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Abstract
Background: Imatinib mesylate has been the standard therapeutic treatment for chronic myeloid leukemia,
advanced and metastatic gastrointestinal stromal tumor (GIST). It is well tolerated with mild adverse effects.
Gynecomastia development during the course of treatment has been rarely reported.
Methods: Ninety-eight patients with advanced or recurrent GIST were treated with imatinib mesylate. Among the
fifty-seven male patients six developed gynecomastia during the treatment. The lesions were confirmed by
sonography. Sex hormone levels were determined in six patients with and without the presence of gynecomastia
respectively. The patients with gynecomatia were treated with tamoxifene and the sex hormones were assayed
before and after tamoxifene treatment.
Results: In patients with gynecomastia the lump underneath the bilateral nipples was 2.5 to 5 centimeters in
diameter. Their serum free testosterone levels ranged between 356.61 and 574.60 ng/dl with a mean ± SD of
408.64 ± 82.06 ng/dl (95% CI 343.03~474.25 ng/dl), which is within the normal range. The level of serum estradiol
was 42.89 ± 16.54 pg/ml (95% CI 29.66~56.12 pg/ml). Three patients had higher levels (43.79~71.21 pg/ml) and the
others’ were within normal range of 27.00~34.91 pg/ml. Six patients without the development of gynecomastia
had normal free testosterone. One patient died because of large tumor burden. The sex hormones had no
significant changes before and after tamoxifene treatment.(P > 0.05)
Conclusions: Testosterone levels were not decreased in the six GIST patients with gynecomastia. Three patients
had increased serum estradiol level which suggests that imbalance of sex hormones may be the cause of
gynecomastia during treatment with imatinib mesylate.
Background
The substantial efficacy of imatinib mesylate in the treat-
ment of advanced and recurrent gastrointestinal tumors
(GISTs) has been confirmed by clinical trials in the past
decade. It has been considered as the standard treatment
for GIST and chronic myeloid leukemia(CML) world-
wide. Imatinib mesylate is well tolerated with only mild
adverse effects, such as edema, nausea, vomiting, diar-
rhea, skin rash, fatigue, cramps and arthalgia, etc [1]. In
general, mild degree of anemia and neutropenia are com-
m o nw h e ng i v e nas t a n d a r dd o s a g e ,b u tt h e ya r ee a s i l y
controlled and no discontinuation of therapy is needed.
Gynecomastia is an uncommon manifestation during the
course of imatinib mesylate treatment. So far, there have
been only two reports about this event [2,3]. Recently
there was a report about the relationship between Dasati-
nib and gynecomastia [4]. The present study reported
our experience in a single institution in China.
Methods
From January 2005 to December 2010, 98 consecutive
patients were treated for advanced or recurrent GIST in
our department. They included 57 male patients, six of
them developed gynecomastia during imatinib mesylate
treatment. The lesions were confirmed by clinical exami-
nation and sonography. The median age was 62.0 years
(range 35 ~76). The median duration of imatinib mesylate
intake was 8.0 months (range 5~20 months). Imatinib
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any medium, provided the original work is properly cited.mesylate 400 mg daily was given in one dose. All patients
had prior surgery for GIST and had recurrence or metas-
tasis of their diseases. Two patients had disseminated
intra-peritoneal tumors and four patients had liver metas-
tases. Sex hormone levels were measured in six patients
with and without the presence of gynecomastia respec-
tively. Written informed consent was obtained from all
patients, and the protocol for this study was approved by
the Ethics Committee of Xiangya Hospital, CSU (No.
KY2010-32).
Quantitative values were presented as mean ± SD.
Student’s t test was used to compare the differences of
sex hormones before and after tamoxifene treatment.
Statistical analyses were performed using the SPSS soft-
ware (version 13.0, Chicago, USA). All tests were two-
tailed and differences were assumed as significant at
P values of less than 0.05.
Results
All six patients complained of painful lump under bilat-
eral nipples during monthly clinical evaluation.On exami-
nation, the lumps were 2.5 to 5 centimeters in diameter
with bilateral occurrence (Figure 1). Only one patient
(76 years old) reported decrease in sexual activity but
without impotence. Laboratory studies indicated that
these six gynecomastia patients’ serum free testosterone
ranged from 356.61 to 574.60 ng/dl with a mean ± SD of
408.64 ± 82.06 ng/dl (95% CI 343.03~474.25 ng/dl),
which is within the normal range (our laboratory normal
value was 241~847 ng/dl). The mean level of serum
estradiol measured was 42.89 ± 16.54 pg/ml (95% CI
29.66~56.12 pg/ml). Three patients had higher levels
(43.79~71.21 pg/ml) and the others’ were within normal
range, 27.00~34.91 pg/ml (our laboratory normal value
was 11.6~41.2 pg/ml). Blood samples taken from six ran-
domly selected patients who do not have gynecomastia
showed normal results of free testosterone, mean ± SD of
424.96 ± 94.37 ng/dl (95% CI 349.18~500.20 ng/dl). Liver
function tests were normal in five of the six patients. The
another patient suffered from chronic hepatitis B had an
increase in serum transaminase and total bilirubin. He
was referred to the hepatologist for further care. His
serum free testosterone was normal but estradiol was
higher than normal range with a reading of 71.21 pg/ml.
Imatinib mesylate treatment was continued and no
dosage adjustments were done. Tamoxifene citrate 20 mg
daily was given to all patients with gynecomastia exclud-
ing the one with hepatitis B, the duration is 8-27 weeks.
The sex hormones of the patients with gynecomastia
were assayed before and after tamoxifene treatment, as
showed in Table 1. All sex hormones had no significant
changes before and after tamoxifene treatment(P > 0.05).
During the follow-up one patient (49 years) died at 16
months after the beginning of imatinib mesylate treatment
due to large burden of liver metastases. His overall survival
w a s3 5m o n t h sa n dp r o g r e s s i o nf r e es u r v i v a lw a s1 2
months. The other five patients were in good condition.
The breast lesions completely disappeared in two patients
and decreased in size in three.
Discussion
Gynecomastia is defined as enlargement of the glandular
tissue in the male breast. It is often found incidentally
and ignored. In contrast, symptomatic gynecomastia is
less common. The lesion is usually bilateral, but may pre-
sent with unilateral mass, which is firm, mobile and disc-
like, centrally located under the nipple-areola complex
[5]. On palpation it is painful and tender. The pathologic
findings of gynecomastia include hyperplasia of ductal
epithelium, inflammatory cells infiltration of the periduc-
tal stroma and increased alveolar fat [6]. The pathophy-
siological process of gynecomastia includes imbalance
between free estrogen and androgens acting in the breast
tissue. This imbalance may occur through multiple
mechanisms. Elevation of serum estrogen may result
from estrogen secreting tumor, such as testicular or adre-
nocortical tumors. It may also be caused by an increased
extra-gonadal conversion of androgen to estrogen by
Figure 1 54 year old man developed gynecomastia after
receiving imatinib for five months.
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Page 2 of 5Table 1 Sex hormones of gynecomastia patients before and after tamoxifene treatment
Gynecomatia Age FSH
(IU/L)*
LH
(IU/L)#
Freet estosterone
(ng/dl)※
Estradiol
(pg/ml)§
17-OHP
(nmol/L)▲
before
tamoxifene
after
tamoxifene
before
tamoxifene
after
tamoxifene
before
tamoxifene
after
tamoxifene
before
tamoxifene
after
tamoxifene
before
tamoxifene
after
tamoxifene
1 35 7.0 8.2 8.2 7.8 574.6 582.4 27.0 26.6 3.0 3.3
2 70 3.2 4.0 6.6 7.3 384.2 375.6 43.8 44.2 4.5 3.9
3 76 8.5 7.5 3.0 4.0 356.6 366.1 34.9 35.0 4.2 4.4
4 75 5.9 6.2 4.6 4.5 385.1 392.4 51.0 49.3 1.6 2.0
5 54 11.0 9.4 3.5 5.0 369.5 350.2 29.3 31.2 3.8 3.1
6☆ 49 9.3 NA 5.4 NA 381.4 NA 71.2 NA 4.6 NA
*Normal value 1.5–12.5IU/L #Normal value 1.7–8.6IU/L ※Normal value 241.0-847.0 ng/dl
§Normal value 11.6-41.2 pg/ml ▲Normal value 0.6-5.4 nmol/L NA: not assayed.
☆The patient suffered from hepatitis B and tamoxifene was not given to him.
Abbreviations: FSH, follicle-stimulating hormone; LH, luteinizing hormone; 17-OHP, 17-hydroxyprogesterone.
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5tissue aromatase [7]. Imbalance between testosterone and
estrogen is caused by some kinds of sex hormone-bind-
ing globulin, which may be present in hyperthyroidism,
chronic liver diseases and the use of medications, such as
spironolactone. Spironolactone can block androgen pro-
duction, block androgens from binding to their receptors,
and increase both total and free estrogen levels [8,9].
During the course of imatinib mesylate treatment, there
were three GIST patients who had received low dose
spironolactone (20 mg daily) occasionally. However,
gynecomastia did not occur in these three patients.
Gambacorti-Passerini et al measured hormone concen-
tration in 38 men receiving imatinib for chronic leukemia
at baseline and during treatment. Seven cases of gyneco-
mastia were noted (18%) [2]. The incidence of gyneco-
mastia is about 10% in our cohort patitents, which seems
higher than we expected in clinical practice. The first rea-
son we speculated may be that the patient felt shy and
was reluctant to report his discomfort to physician. The
second reason may be that the physicians apt to ignore
this abnormality during regular physic examination On
the contrary, we surgeons may be more sensitive to the
changes of surgical condition.
Receptor tyrosine kinases c-Kit and platelet-derived
growth-factor receptors alpha (PDGFRa) are expressed in
the testis. They are believed to be involved in the bio-syn-
thetic process of testosterone. Imatinib mesylate inhibits
both c-Kit and PDGFRa and thus the production of testos-
terone may be decreased during its administration. Sec-
ond-generation TKIs, such dasatinib and nilotinib, are
multi-target inhibitor, including receptor tyrosine kinases
c-Kit and PDGFRa. In fact, dasatinib exerts a more potent
inhibitory action on c-Kit and PDGFRa [10]. Caocci et al
reported a male patient suffered gynecomastia after treat-
ment with dasatinib for CML [4].
In comparison of hormone concentration before and
during imatinib treatment Gambacorti-Passerini et al
found that patients who developed gynecomastia had more
reduction in free testosterone concentration than those
who did not [2]. Kim et al reported a patient who devel-
oped gynecomastia when treated with imatinib for GIST
and demonstrated a lower serum concentration of testos-
terone and decreased libido. The patient concurrently had
hydrocele of the testis which was improved when imatinib
was discontinued, but the lesion recurred when the treat-
ment was restarted. The authors concluded that inhibition
of c-Kit and PDGFRa is the cause of the lesions described
[3]. Animal studies demonstrated that PDGF signaling may
constitute a common mechanism in the control of multiple
steroidogenic lineages, and the c-Kit gene plays a funda-
mental role during the establishment, the maintenance and
the function of germ cells [11-13].
In this study we did not find a decrease in free testoster-
one level in our patients with gynecomastia. There was no
significant difference of free testosterone level in patients
with or without gynecomastia who were taking regular
dose (400 mg daily) of imatinib. In addition, our patients
with gynecomastia do not have changes in their sexual
behavior except one who was 76 years old with decreased
libido. The factor of aging cannot be ruled out in this case.
The increase in estrogen levels in half of our patients
seems to suggest that an imbalance of sex-hormones may
be the cause of gynecomastia development.
Generally there are three options for the treatment of
gynecomastia, including radiation, surgery and medical
therapy. Medicines including androgens, antiestrogens,
aromatase inhibitors, danazol have been used to treat
gynecomastia [14]. Our patients with gynecomastia had a
good response to tamoxifene administration. Since imati-
nib metabolized in vivo mainly through CYP3A4, and
tamoxifene is a substrate of CYP3A4. Their concomitant
use may enhance the effect of tamoxifene [15].
Conclusions
Although there was no special medications except imati-
nib taken by our patients before the develop of gyneco-
mastia, the small sample size in this study prevents us to
reach any conclusion at this point. So far there has not
been a single publication regarding gynecomastia in the
toxicity profile studies of imatinib mesylate. Given the fact
that thousands of patients with chronic myeloid leukemia
or GIST have received imatinib mesylate, it is unlikely that
the breast lesions have been unnoticed. The purpose of
the present report is to call for attention to this uncom-
mon event, further study is warranted.
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